Benzinga · Feb 24, 2026
NASDAQ · MGNX
MacroGenics, Inc.
Healthcare · Biotechnology
$2.33
Down-$0.07 (-2.92%)
Updated Nov 3, 2026, 2:08 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 89.51M
- P/E ratio
- -1.18
- Dividend yield
- 0.00%
- 52-week range
- $1.29 – $5.08
- Volume
- 767.7K
- Avg. volume
- 946.23K
Price performance · MGNX
MGNX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
MGNX closed at $2.33 after 21 trading sessions, down 38.20% for the selected period.
- Last close
- $2.33
- Period change
- -38.20%
- Period low
- $2.19
- Period high
- $3.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $2.41 | $2.535 | $2.32 | $2.33 | 767.7K |
| Oct 30, 2026 | $2.37 | $2.435 | $2.235 | $2.40 | 1.18M |
| Oct 29, 2026 | $2.49 | $2.59 | $2.37 | $2.38 | 744.48K |
| Oct 28, 2026 | $2.39 | $2.545 | $2.35 | $2.47 | 1.41M |
| Oct 27, 2026 | $2.20 | $2.5598 | $2.1579 | $2.44 | 2.12M |
| Oct 26, 2026 | $2.09 | $2.23 | $1.93 | $2.19 | 2.61M |
| Oct 23, 2026 | $3.55 | $3.565 | $2.13 | $2.25 | 4.01M |
| Oct 22, 2026 | $3.59 | $3.67 | $3.52 | $3.63 | 465.52K |
| Oct 21, 2026 | $3.45 | $3.665 | $3.45 | $3.59 | 398.27K |
| Oct 20, 2026 | $3.35 | $3.60 | $3.33 | $3.49 | 325.41K |
| Oct 19, 2026 | $3.27 | $3.435 | $3.26 | $3.33 | 567.62K |
| Oct 16, 2026 | $3.37 | $3.45 | $3.235 | $3.25 | 410.56K |
| Oct 15, 2026 | $3.34 | $3.435 | $3.30 | $3.37 | 578.09K |
| Oct 14, 2026 | $3.42 | $3.42 | $3.19 | $3.31 | 906.75K |
| Oct 13, 2026 | $3.73 | $3.73 | $3.38 | $3.42 | 559.14K |
| Oct 12, 2026 | $3.72 | $3.76 | $3.655 | $3.72 | 284.72K |
| Oct 9, 2026 | $3.53 | $3.785 | $3.52 | $3.74 | 418.44K |
| Oct 8, 2026 | $3.53 | $3.615 | $3.41 | $3.55 | 768.07K |
| Oct 7, 2026 | $3.60 | $3.73 | $3.525 | $3.55 | 509.98K |
| Oct 6, 2026 | $3.79 | $3.79 | $3.55 | $3.64 | 633.29K |
| Oct 5, 2026 | $3.65 | $3.855 | $3.495 | $3.77 | 605.94K |
Latest MGNX news
The latest Smart Investors Daily articles mentioning MGNX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MGNX research
Overview
Company profile and research snapshot.
Company profile
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.44
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | B. Riley Securities | Buy | — |
| Apr 20, 2026 | Barclays | Overweight | — |
| Apr 10, 2026 | B. Riley Securities | Buy | — |
| Mar 10, 2026 | Barclays | Overweight | — |
| Nov 3, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Why Is MacroGenics Stock Sinking Tuesday?
MacroGenics sees stock decline after FDA places partial clinical hold on Phase 2 LINNET study due to safety concerns.
Benzinga · Feb 24, 2026
Reported Earlier, MacroGenics Pauses Enrollment In LINNET Study As FDA Imposes Partial Clinical Hold Following Serious Safety Events In Gynecologic Cancer Patients
Yahoo · Jan 27, 2026
January 2026's Top Penny Stocks To Watch
Major stock indexes in the United States presented a mixed picture recently, with the S&P 500 reaching an all-time high while the Dow Jones Industrial Average faced downward pressure. Despite these fluctuations, investors continue to explore diverse opportunities across various sectors. Penny stocks, often associated with smaller or newer companies, remain a compelling area for those seeking affordable entry points and potential growth. These stocks can offer significant value when they are...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
